Clinical Trials · NCT05114590

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

Name: Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Lixisenatide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Sanofi
Enrollment: 124
Start date: Jan 2022
Locations: 18 sites, United States
Primary endpoint: Change From Baseline to Week 16 in the Percentage of Time in Range [70 to 180 Milligram Per Deciliter (mg/dL)]

View Lixisenatide compound reference